CypD-IN-1 is a potent and subtype-selectivecyclophilin E (CypE)inhibitor. CypD-IN-1 has CypE affinity withIC₅₀andK_ivalues of 0.013 μM and 0.072 μM, respectively. CypD-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging,autophagyand diabetes^[1].

IC50: 0.52 μM (CypD); 1.8 μM (CypA); 5.6 μM (CypB); 0.072 μM (CypE); 0.03 μM (CypE K212A); 2 μM (CypE K217A); 0.019 μM (CypE K218A)^[1]
IC50: 0.6 μM (CypD); 3 μM (CypA); 4 μM (CypB); 0.013 μM (CypE); 17 μM (CypC); 40 μM (CypG)^[1]

CypD-IN-1 (C3A) has selectivity for CypD, CypA, CypB and CypE with K_ivalues of 0.52 μM, 1.8 μM, 5.6 μM and 0.072 μM, respectively^[1].
CypD-IN-1 has inhibitory activity for CypD, CypA, CypB, CypE, CypC and CypG with IC₅₀values of 0.6 μM, 3 μM, 4 μM, 0.013 μM, 17 μM and 40 μM, respectively^[1].
CypD-IN-1 has binding and inhibition potency for CypE K212A, K217A and K218A mutants with IC₅₀values of 0.03 μM, 2 μM and 0.019 μM, respectively^[1].

840.73

C₄₆H₄₉BN₆O₉

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.